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Abstract
Dexamethasone (Dex) and radiation therapy are established modalities in multiple myeloma. In this study, we pro-
pose a novel combination of Dex plus radiation that shows superior clonogenic cell killing and apoptosis ofmyeloma
cells and selectively eliminates myeloma cells when cocultured with bone marrow stromal cells (BMSCs). Dex was
found to inhibit the release of interleukin-6 from irradiated BMSCs, which is an establishedmyeloma cell proprolifera-
tive cytokine. In 5TGM1 model, the combination of Dex with skeletal targeted radiotherapy (153-Sm-EDTMP) pro-
longed median survival time and inhibited radiation-induced myelosuppression. A two-cycle treatment of Dex plus
153-Sm-EDTMP was well tolerated and further improved median survival time. Mechanistically, Dex increased super-
oxide and hydrogen peroxide production and augmented radiation-induced oxidative stress and cell death ofmyeloma
cells. In contrast, Dex inhibited radiation-induced increase in pro-oxidant levels and enhanced the clonogenic survival
in normal hematopoietic stem and progenitor cells. Treatmentwith eitherN -acetylcysteine or the combination of poly-
ethylene glycol (PEG)–conjugated copper, zinc-superoxide dismutase, and PEG-catalase significantly protected mye-
loma cells from Dex-induced clonogenic death. Overall, these results demonstrate that Dex in combination with
radiotherapy enhances the killing of myeloma cells while protecting normal bone marrow hematopoiesis through
a mechanism that involves selective increases in oxidative stress.
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Introduction
Radiation therapy is a powerful treatment modality for multiple mye-
loma (MM) [1,2]. External beam irradiation is frequently used for
palliation of bone pain and eradication of solitary plasmacytomas
[3,4]. In myeloma patients who present diffused bone disease, sys-
temic radiotherapy with agents such as bone-seeking radionuclides
and radioimmunotherapy [5,6] or alternative techniques like intensity-
modulated radiation therapy and helical tomography [7,8] have been
explored. Bone-seeking radionuclide therapy with radioactive samar-
ium conjugated to a tetraphosphonate chelator (153-Sm-EDTMP)
has been used in myeloablative clinical protocols for MM [9–12].
The combination of radiotherapy with novel chemotherapeutic agents
such as thalidomide [13] and bortezomib [14,15] has shown good clin-
ical outcomes with reduced radiotoxicity to normal tissues. Testing of
antimyeloma drugs in combination with bone-seeking radiotherapy is
worthy of investigation because MM is an inherently radiosensitive
malignancy. Furthermore, such radiation-based combination regimens
may require less aggressive interventions (nonmyeloablative) that could
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be offered to elderly patients who comprise the present and future ma-
jority of MM patients [16,17].
Dexamethasone (Dex) is a synthetic steroidal glucocorticoid that is
widely used in the treatment of MM in single [18] and combination
chemotherapy regimens [19]. The antimyeloma effect of Dex has
been partly elucidated [20,21]. The major impediments to the effec-
tive use of Dex in myeloma cure are acquired Dex resistance due to
prolonged usage and/or disease progression [22,23] and toxicities
with combination chemotherapy agents without an improved survival
benefit [24]. Dex is also an anti-inflammatory drug that inhibits the
activation of the redox-regulated prosurvival transcription factors nuclear
factor κB (NF-κB) and activator protein 1 (AP-1) that govern cellular
radiosensitivity [25]. Dex has been shown to inhibit IL-6 expression
[26], and an NF-κB– and c-Jun–mediated IL-6 expression has been
reported in myeloma cells [27]. IL-6 has been established as a prosurvival
and proproliferative cytokine in MM [28] that may be regulated by the
redox status of the tumor cells [29]. On the basis of the direct myeloma
cytotoxicity and anti-inflammatory nature of Dex, we hypothesized that
Dex-induced redox perturbations could potentially augment radiation-
induced myeloma cell death by enhancing oxidative stress.
Myeloma cells may exist in a pro-oxidant state as evidenced by in-
creased markers of lipid peroxidation and lower levels of antioxidant
enzymes in patients with MM, relative to healthy controls [30–32].
Dex has been suggested to induce oxidative cell death in T-cell lym-
phoma [33–35]; however, a clear role for Dex in inducing oxidative
stress in MM has not been established [36,37]. In normal cells, Dex
has been shown to inhibit reactive oxygen species (ROS) generation in
mononuclear cells and polymorphonuclear leukocytes [38], protect
hepatocytes against cadmium toxicity by increasing levels of metal-
lothionein and cellular thiols [39] and reduce oxidative DNA fragmen-
tation induced by hydrogen peroxide (H2O2) in the nasal mucosa
[40]. It is well established that ionizing radiation (IR) actuates the pro-
duction of free radicals (such as superoxide [O2
•−] and H2O2) that in-
duce oxidative stress–induced cell death [25]. Because myeloma cells
seem to demonstrate increased levels of endogenous metabolic oxida-
tive stress, relative to normal cells, and radiation is a potent exogenous
inducer of oxidative stress, we hypothesized that combining radiation
with Dex would selectively augment the killing of myeloma cells rela-
tive to bone marrow (BM)–resident cells.
This study shows that Dex can be effectively combined with radiation
to improve therapeutic efficacy in MM. Mechanistically, Dex selec-
tively induces oxidative stress–induced cell killing in myeloma cells
compared with BM stromal cells and hematopoietic stem/progenitor
cells. This study provides a new paradigm for Dex usage in MM that
can potentially be incorporated in designing more effective combined
modality therapies.
Materials and Methods
Cell Culture
Cell lines were obtained from the American Type Culture Collec-
tion (RPMI 8226 [CCL-155], SR-4987 [CRL-2028], and HS-5
[CRL-11882]; ATCC,Manassas, VA) or were kind gifts fromDr Steven
Rosen (MM.1S and MM.1R; Northwestern University, Chicago, IL),
Dr Greg Mundy (5TGM1; University of Texas Health Science Center
at SanAntonio, TX),Dr Toshiyuki Yoneda (5TGM1-Luc;University of
Texas Health Science Center at San Antonio, TX), or Dr Diane Jelinek
(KAS-6/1 and ANBL-6; Mayo Clinic, Rochester, MN). 5TGM1 cells
stably expressing emerald fluorescent protein (eFP) alongwith firefly lucif-
erase (Luc) protein (5TGM1-eFP-Luc) was generated using a viral vector
harboring the eFP and Luc transgene under control of the spleen focus–
forming virusU3promoter with an internal ribosome entry site. Similarly,
SR-4987 cells stably expressing red fluorescent protein (SR-4987-DsRed)
were established. All cell lines were grown in RPMI 1640 medium
(Gibco, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (Gibco), 100 U/ml penicillin (Gibco), 100 mg/ml streptomycin
(Gibco), and 50μM β-mercaptoethanol (referred to as completemedium)
in a humidity-controlled incubator (37°C and 5% CO2).
The normal hematopoietic stem cells (HSCs) and hematopoietic pro-
genitor cells (HPCs) were isolated fromC57BL/6mice (8-10weeks old)
that were purchased from The Jackson Laboratory (Bar Harbor, ME)
and housed at The University of Iowa Animal Care Facility. The Insti-
tutional Animal Care and Use Committee approved the animal proce-
dures used in this study. Briefly, BMwas collected frommice (n = 10 per
experiment), and a lineage-negative (Lin−) cell population was iso-
lated (Stem Cell Technologies, Inc). Cells were separated into HPCs
(Lin−c-kit+Sca1− or LKS− cells) and HSCs (Lin−c-kit+Sca1+ or LKS+
cells) LKS+ population [41].
Propidium Iodide Uptake
The percentage of dead cells was determined by a propidium iodide
(PI) uptake assay. Cells (2.5 × 104 for myeloma cells and 0.5 × 104 for
BMSCs) were seeded in 96-well flat-bottom plates, in a phenol red–free
RPMI 1640 (Gibco) complete medium. Triplicate wells were treated
with 0, 1, or 5μMDex (Sigma-Aldrich, St Louis,MO) for 24 or 48 hours
and then left untreated or subjected to radiation treatment (6 Gy). All
irradiations were performed at the Radiation and Free Radical Core Fa-
cility (The University of Iowa Holden Comprehensive Cancer Center),
using a cesium-137 γ radiation source at a dose rate of 0.83 Gy/min.
At 24 hours after radiation, PI (Sigma-Aldrich) was added (1 μg/ml in
PBS), plates were incubated for 60 minutes at 37°C, and fluorescence
wasmeasured (InfiniteM200; Tecan, Research Triangle Park, NC; λex =
530 nm, λem = 645 nm). The percentage of dead cells was calculated as
the proportion of fluorescence intensity relative to that in the untreated
control (the latter being set at 100% viability).
Clonogenic Assays
The colony-forming ability of cell lines and primary cells was de-
termined as described before with minor modifications [42]. Cells
were treated without or with Dex (5 μM for 12 hours) and then left
untreated or given radiation (6 Gy). In specific experiments, the glu-
tathione precursor N -acetylcysteine (NAC, 10 mM; Sigma-Aldrich)
was added 1 hour beforeDex. After various treatments, cells weremoved
to ice and plated (in triplicate) in basic methylcellulose medium (Stem
Cell Technologies Inc, Vancouver, British Columbia, Canada) for mye-
loma cells or complete medium for BMSCs. The plating efficiency of
cell lines was calculated by the following formula: PE = (number of col-
onies counted/number of cells seeded) × 100. Survival fractions were
calculated as follows: (number of colonies counted)/(number of cells
seeded × PE). For each cell population, the normalized survival fraction
(NSF), relative to the number of untreated control cells, was calculated.
The plating efficiencies of ANBL-6, 5TGM1, HS-5, and SR-4987
were 30, 28, 20, and 27.2, respectively.
For analyzing the colony-forming ability of HPCs or HSCs, cells
were treated without or with Dex (5 μM for 6 hours) followed by
mock or 6 Gy of radiation. Cells were plated in methylcellulose me-
dium containing recombinant cytokines and erythropoietin (Stem
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Cell Technologies, Inc). Plates were incubated at 37°C for 6 days and
PE (12 and 8 hours for HSCs and HPCs, respectively), and the NSF
was calculated.
JC-1 Staining
Loss of mitochondrial membrane potential was measured using the
MitoProbe JC-1 assay (Molecular Probes, Invitrogen). The seeding
density and medium for myeloma and BMSCs was similar to the PI
assay followed by treatment with Dex (5 μM for 24 hours) and/or ra-
diation (6 Gy). Cells were treated with the proton ionophore carbonyl
cyanide 3-chlorophenylhydrazone (50 μM) to obtain positive con-
trols. Six hours after radiation, the cells were incubated with JC-1
(200 nM) at 37°C for 30 minutes in the dark and were read using a
plate reader (Tecan; λex = 485 nm, λem = 595 nm for red fluorescence
and λex = 485 nm, λem = 535 nm for green fluorescence). For each
sample, the average of triplicate samples was taken, and the ratio of
red/green fluorescence intensity was calculated.
Caspase-3 Activity Assay
Apoptosis was measured using a caspase-3 fluorescence assay (Cayman
Chemical Company, Ann Arbor, MI). Myeloma cells (1.0 × 104 cells/
well) or BMSCs (0.2 × 104 cells/well) were seeded in 96-well plates
in complete medium in triplicate and then treated with Dex (5 μM
for 24 hours) and/or radiation (6 Gy). Lysates were collected 12 hours
after radiation (without or with caspase-3 inhibitor N-Ac-Asp-Glu-Val-
Asp-CHO) and used to measure caspase-3 activity (Tecan; λex = 485
nm, λem = 535 nm). Caspase-3 activity was calculated and expressed as
units per milligram of total protein.
Western Blot Analysis
Myeloma cells were treated with Dex (5 μM for 24 hours) and/or
radiation (6 Gy), and total cell lysates were prepared 24 hours after
radiation, using lysis buffer (Santa Cruz Biotechnology Inc, Santa Cruz,
CA) supplemented with a protease-inhibitor cocktail. The anti–poly
ADP-ribose polymerase (PARP) antibody with specificity toward
both the full-length (113 kDa) and the cleaved large fragment of PARP
(89 kDa) or α-tubulin (Cell Signaling Technology, Inc, Danvers, MA)
antibody was used. Blots were developed using enhanced chemilumi-
nescence (Pierce Biotechnology, Rockford, IL). Densitometric analyses
for protein quantification were carried out using Image J 1.38x soft-
ware (http://rsbweb.nih.gov/ij/index.html).
In Vitro Coculture Studies
Cocultures of 5TGM1-eFP-Luc MM cells and BMSCs (SR-4987
or SR-4987-DsRed) were established. Briefly, BMSCs were plated in
complete medium in 96-well plates (2 × 102 cells/well, in triplicate) and
allowed to adhere for 12 hours. 5TGM1-eFP-Luc cells (2 × 103 cells/
well) were then added alone (monoculture) or cocultured with the
BMSCs for 24 hours. Wells were then either left unirradiated or
exposed to 6 Gy of radiation. At 24 and 48 hours after radiation, a
luciferase assay (Promega, Inc, Madison, WI) was performed, and re-
sults were compared with time 0. The fluorescence images of 5TGM1-
eFP-Luc and SR-4987-DsRed in coculture were acquired using an
inverted fluorescence microscope (Eclipse TS-100F; Nikon, Melville,
NY [magnification, ×40]) with Chroma filter sets fluorescein isothio-
cyanate (λex = 480, band-pass = 40 nm; λem = 535, band-pass =
40 nm) and Cy3 (λex = 535, band-pass = 50 nm, λem = 610, band-pass =
75 nm), respectively.
ELISA
5TGM1 (5 × 105 cells/well) or SR-4987 cells (1 × 105 cells/well)
were seeded in six-well plates in complete medium overnight. Cells were
treated with Dex (5 μM for 24 hours) followed by radiation (6 Gy), and
culture supernatants were collected 24 hours after radiation. Controls
included no treatment, Dex alone, and radiation alone. IL-6 levels in
the supernatant were measured using a commercially available ELISA
kit (eBiosciences, San Diego, CA).
3-(4, 5-Dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
Bromide Assay
The proliferative support of conditioned supernatant obtained from
SR-4987 cells (CM) or SR-4987 cells exposed to 6-Gy radiation treat-
ment (irradiated cell conditioned medium [ICCM] 24 hours after ra-
diation) or exogenous IL-6 (50 ng/ml; R&DSystems,Minneapolis,MN)
was determined by 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide (MTT) assay (ATCC) as described before [43]. 5TGM1 cells
(1 × 104 cells/well in a 96-well plate) were seeded in triplicates using
CM, ICCM, or IL-6 supplemented medium. At 48 hours, MTTassay
was performed, and absorbance was read at 570 nm (Tecan). The rela-
tive proliferation at 48 hours for untreated control was set to 1, and the
fold change with treatments was calculated.
In Vivo Therapy Studies
Experiments with 153-Sm-EDTMP (imaging and survival studies)
were carried out at theMayo Clinic, Rochester,MN, in accordance with
the guidelines of the Mayo Clinic Animal Use and Care Committee.
153-Sm-EDTMP was provided by Cytogen Corporation (Princeton,
NJ). A syngeneic, orthotopic mouse model of 5TGM1-Luc myeloma
in C57BL/KaLwRij mice (Harlan CPB, Horst, The Netherlands) was
used as described by us previously [42,44]. In vivo treatments were started
on day 12 after tumor implantation, with the cohorts (n = 6mice/group)
treated with 1) phosphate buffered saline (PBS), days 12 to 16; 2) Dex
(Dex phosphate; American Pharmaceutical Partners, Inc, Schaumburg,
IL) at 1 mg/kg body weight, days 12 to 16; 3) 153-Sm-EDTMP at
22.5 MBq, day 13; or 4) Dex plus 153-Sm-EDTMP. Both Dex and
153-Sm-EDTMPwere injected intraperitoneally. Complete blood cell
counts were carried out on days 12 (baseline count), 18, and 21 after
tumor cell inoculation, using a blood analyzer (VetScanHM II; Abaxis,
Union City, CA) at the Toxicology and Pharmacology Laboratory
(Mayo Clinic). In addition, tumor burden was evaluated in a noninvasive
manner, on days 18 and 24 after tumor cell injection, using the IVIS
200 Bioluminescence Imaging System (Xenogen Corp, Hopkinton,
MA). In the repeat dosing regimen, the first cycle of treatment was ini-
tiated on day 12 (as in the one-cycle regimen) followed by a second
cycle of treatment initiated on day 22, where Dex was given on days
22 to 26 and 153-Sm-EDTMPwas given on day 23. For survival stud-
ies, mice were followed until they reached the humane end point.
Measurements of Intracellular Superoxide (O2
•−) Levels
Steady-state levels of O2
•− were estimated using the fluorescent dye,
dihydroethidium (DHE;Molecular Probes, Invitrogen). 5TGM1 (2.5 ×
104/well) or SR-4987 cells (5 × 103/well) were seeded in 96-well plates
(in triplicate) in phenol red–free complete medium. After 12 hours,
cells were treated with Dex (5 μM for 24 hours), followed by no treat-
ment or radiation (6 Gy), and then cultured for 6 hours. Dye labeling
was done at 37°C for 30 minutes in PBS (containing 5 mM pyruvate)
with DHE (10 μM; in 0.1% DMSO). To confirm that increases in
DHE oxidation were indicative of changes in intracellular O2
•−, specific
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wells were pretreated with PEG-SOD (100 U/ml for 1 hour) before
and during DHE labeling. DHE oxidation was measured at λex =
488 nm and λem = 650 nm (Tecan).
Measurements of Steady-State Levels of
Intracellular Pro-oxidants
Pro-oxidant levels (presumably intracellular peroxides) were moni-
tored using 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein di-
acetate (carboxy-H2DCF-DA;Molecular Probes, Invitrogen) oxidation.
Cells were seeded in 96-well plates similar to DHE protocol and treated
with Dex (5 μM), preloaded with carboxy-H2DCF-DA (10 μg/ml for
30 minutes) followed by radiation (6 Gy). The fluorescence of the
oxidized probe was measured at 6 hours after radiation (Tecan; λex =
495 nm, λem = 530 nm). To ascertain if H2DCF-DA oxidation was
due to H2O2, specific wells were pretreated with 100 U/ml PEG-catalase
for 1 hour before the addition of Dex. For the positive control, cells
were treated with H2O2 (100 nM for 1 hour) before the probe was
added. For experiments with HSCs and HPCs, the cells were seeded
overnight in 96-well plates (1.0 × 104/well, in triplicate). Dex and ra-
diation treatments were similar to treatment of cell lines as described
above. Specific wells were pretreated with NAC (10 mM for 1 hour)
before the addition of Dex followed by irradiation and H2DCF-DA
oxidation was measured using a plate reader.
Statistical Analysis
GraphPad Prism 4.0 software (GraphPad Software, San Diego,
CA) was used for data handling, analysis, and presentation. Statistical
significance was determined using two-tailed unpaired t test with a
confidence interval of 95%. Survival curves were generated using the
Kaplan-Meier method, and the log-rank test was used to examine the
significance of differences in survival between the groups.
Results
Dexamethasone Increases IR-induced Myeloma
Cell Death In Vitro
In a panel of myeloma cells, we first assessed the cytotoxicity of
Dex (1 μM) at both 24 and 48 hours after treatment. Both human
(MM.1S, 8226, KAS-6/1, and ANBL-6) and a murine myeloma cell
line (5TGM1) showed sensitivity to Dex-induced toxicity with a time-
dependent increase in cell death (Figure 1A). Next, Dex (5 μM for
24 hours) was combined with radiation, and cell death was assessed
at 24 hours after radiation treatment. Dex treatment inducedmyeloma
cell killing with drug sensitivity similar to that observed in Figure 1A
and radiation alone did not result in immediate cell death of myeloma
cells. However, pretreatment with Dex significantly increased PI stain-
ing in all myeloma cell lines after radiation treatment. The results of
Figure 1B support the hypothesis that Dex may be acting as a radio-
sensitizing drug in myeloma cell lines.
Clonogenic cell survival assays were performed to confirm the
ability of Dex to sensitize myeloma cell lines to radiation treatment
(Figure 1C ). Treatment with Dex resulted in approximately 50% to
60% clonogenic reduction for myeloma cells and radiation alone
caused approximately 60% and 30% reduction in the clonogenicity
of ANBL-6 and 5TGM1 cells, respectively. When myeloma cells were
pretreated with Dex followed by radiation treatment, the radio-
sensitization effect of Dex was clearly evident with a greater than 90%
reduction in the colony-forming ability of cells compared with untreated
controls. To determine whether Dex-mediated radiosensitization was
specific to myeloma cells and not to other cellular components of
BM, clonogenic assays were performed in twowell-established human-
and mouse-immortalized BMSCs: HS-5 [45] and SR-4987 [46] (Fig-
ure 1C ). BMSCs were found to be relatively resistant to Dex treatment,
whereas exposure to 6Gy of radiation resulted in an approximately 40%
decrease in colony-forming ability of both stromal lines. However, pre-
treatment with Dex did not result in increased clonogenic cell death of
BMSCs when Dex plus radiation treatment was used compared with
radiation alone. Reverse transcription–polymerase chain reaction was
used to confirm the presence of the functional glucocorticoid receptorα
(GRα) isoform in all myeloma and stromal cells used in this study (data
not shown). Together, the results presented in Figure 1 demonstrate
that Dex is selectively cytotoxic to myeloma cells and can selectively
sensitize myeloma cells to radiation treatment.
Dex Plus Radiation Treatment Results in Mitochondrial
Dysfunction and Apoptotic Cell Death of Myeloma Cells
We next determined whether treatment with Dex and/or radiation
induces loss in mitochondrial membrane potential (Δψm) in myeloma
cells (Figure 2A). In myeloma cells, both Dex or radiation treatment
decreased the red/green JC-1 fluorescence ratio, indicative of mito-
chondrial depolarization. When cells were pretreated with Dex fol-
lowed by radiation, a more profound decrease in Δψm was noted in
myeloma cells than that observed after radiation treatment alone. Stud-
ies were extended to BMSCs where Dex pretreatment did not result in a
further decrease in radiation-induced changes in Δψm (Figure 2A).
Overall, the JC-1 results suggest that combined treatment of Dex plus
radiation results in the depolarization of mitochondria that may be re-
sponsible for triggering mitochondrial transition pore opening and cell
death seen by PI staining in Figure 1.
To determine whether Δψm changes result in the activation of
caspase-3, myeloma cells were treated with Dex and/or radiation,
and total caspase-3 activity was measured. For MM.1S cells, a signifi-
cant increase in caspase-3 activity was detected after treatment with
Dex or radiation, and this was further increased by the combination
treatment (Figure 2B). Similarly for 5TGM1 cells, combined treat-
ment of Dex plus radiation led to a significant increase in caspase-3
activity over that observed with Dex or radiation alone. Furthermore,
in BMSCs, the combined treatment of Dex plus radiation did not lead
to a further increase in caspase-3 activity over that seen with radiation
alone. The role of caspase-3 activation in myeloma cell apoptosis was
confirmed by measurement of the cleavage of PARP. With combi-
nation treatment, PARP cleavage was apparent in all myeloma cells
(Figure 2C ). Collectively, the data in Figure 2 support the hypothesis
that myeloma cells treated with Dex plus radiation exhibit increased
cell death over that produced by either agent alone and that this cell
death may involve the mitochondrial pathway of apoptosis.
In Myeloma-BMSCs Cocultures, Dex Plus Radiation
Treatment Selectively Kills Myeloma Cells and Inhibits
Radiation-Induced IL-6 Production from BMSCs
To determine whether Dex plus radiation treatment is effective
within the tumor microenvironment, studies were extended to a direct
myeloma-BMSCs coculture model (Figure 3A). The in vitro prolifera-
tion of 5TGM1-Luc cells (5TGM1 cells expressing a luciferase marker)
was accelerated when cocultured with SR-4987 BMSCs, relative to
when grown as monocultures (Figure 3A). Treatment of coculturedmy-
eloma cells (5TGM1-Luc and SR-4987)withDex resulted in amarginal
inhibition of myeloma cell proliferation, whereas radiation treatment
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induced myeloma cell proliferation compared with untreated control
cells. In contrast, Dex combined with radiation caused significant
myeloma cell killing when compared with any other treatment group
at 24 and 48 hours. To further assess the specificity of Dex plus ra-
diation treatment, cocultures of eFP-expressing 5TGM1 cells and
DsRed-expressing SR-4987 BMSCs were used. With Dex plus radia-
tion treatment, it was apparent that only the 5TGM1 cells were being
killed (Figure 3B). Results obtained from coculture studies (Figure 3,A
and B) suggest that BMSCs are contributing, in a paracrine fashion, to
acquired resistance to radiation in 5TGM1 cells and that the proposed
combination treatment of Dex with radiation is effective in selectively
eliminating the tumor cell population in cocultures.
Given that IL-6 has been established as a proproliferative cytokine
for myeloma cells [47] and shown to be induced by radiation, we next
determined whether irradiated myeloma cells or BMSCs was releasing
IL-6 that may cause increased proliferation of myeloma cells seen in
cocultures. In 5TGM1 cells, treatment withDex or radiation inhibited
IL-6 levels in the supernatant and Dex plus radiation treatment resulted
in IL-6 concentrations lower than the untreated control (Figure 3C ).
For SR-4987 cells, the basal concentration of IL-6 in untreated cells
was 275.1 ± 20.4 pg/ml that was marginally inhibited byDex treatment
(233.9 ± 13.5 pg/ml; Figure 3C ). With 6 Gy of radiation treatment,
the IL-6 concentration in the SR-4987 culture supernatant increased
to 627.5 ± 16.9 pg/ml. Notably, this radiation-induced IL-6 release
by SR-4987 cells was completely blocked by Dex pretreatment, sug-
gesting that irradiated BMSCs predominantly secrete IL-6 and that
Dex can block the proproliferative effects of radiation in a coculture
model system.
To determine whether exogenous IL-6 mimics the proproliferative
effects of irradiated stromal cells, the ability of exogenous IL-6 and the
culture medium obtained from irradiated BMSCs (ICCM) to stimu-
latemyeloma cell proliferation was compared. Exogenous IL-6 resulted
in increased 5TGM1 cell viability and proliferation (fold change of
1.3 ± 0.1) relative to tumor cells exposed to culture medium obtained
from nonirradiated SR-4987 cells (Figure 3D). When myeloma cells
were cultured in ICCM, a more pronounced increase in 5TGM1 pro-
liferation was observed (1.7 ± 0.1), indicating that in addition to IL-6,
other proinflammatory cytokines released by irradiated BMSCs may
Figure 1. Dex induces myeloma cell cytotoxicity that is enhanced by radiation. Cell lines were treated with Dex and/or radiation, and cell
death was determined by PI uptake (A, B) or clonogenic assay (C). (A) Myeloma cell cytotoxicity by Dex (1 μM) alone at 24 and 48 hours.
*P < .05, ζP < .001 versus 24 hours. (B) Myeloma cell cytotoxicity with treatment of Dex (5 μM) alone, radiation (6 Gy) alone, or Dex plus
radiation at 24 hours. *P< .05 versusDex or IR, ζP< .001 versus IR, #P< .05 versus Dex. For panels A and B, results are mean of triplicate
wells ± SD and representative of two independent experiments. The data are presented as percentage cell death relative to that in un-
treated controls. (C) NSF for myeloma (ANBL-6 or 5TGM1) and BMSCs (HS-5 or SR-4987) after Dex (5 μM) and/or 6 Gy of radiation. The
results are representative of two independent experiments. *P < .0005 versus Dex or IR, ζP < .01 versus control. ns indicates not signifi-
cant. For panels A, B, and C, all statistical comparisons are with the respective cell types.
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be contributing to myeloma cell growth and proliferation. The pres-
ence of an IL-6 receptor complex in 5TGM1 cells was confirmed by
Western blot analysis of whole cell lysates (data not shown). Overall,
Figure 3 shows that with the Dex pretreatment, the release of IL-6 and
other proinflammatory cytokines from irradiated BMSCs is attenuated,
and this may be contributing to radiosensitization of myeloma cells in
stromal cell cocultures.
Dex Enhances Skeletal Targeted Radiotherapy
(153-Sm-EDTMP)-Mediated Tumor Suppression and Protects
Peripheral Blood Cell Counts in the 5TGM1 Myeloma Model
To evaluate if Dex increases the cytotoxicity of radiation therapy
in vivo, Dex was combined with 153-Sm-EDTMP in a systemic mye-
loma model. The response to therapy was measured by biolumines-
cence imaging (BLI) of 5TGM1-Luc cells (Table 1). On day 18 after
radiation, the BLI signal was reduced by Dex or 153-Sm-EDTMP
treatments (P < .005 vs untreated control), which was further decreased
with the combination treatment of Dex plus 153-Sm-EDTMP (P <
.0001 vs untreated control). On day 24, average tumor growth in the
group receiving Dex treatment alone was marginally lower compared
with those in the control group (P < .01), indicating that Dex treat-
ment alone may not be sufficient to inhibit tumor cell proliferation
in vivo. Compared with Dex, 153-Sm-EDTMP exhibited a more pro-
nounced inhibition of tumor growth (P < .005 vs control). In addition,
combined treatment of Dex plus 153-Sm-EDTMP showed no tumor
cell growth between days 18 and 24 (P < .0001 vs control). Further-
more, on day 24, the mean BLI units of Dex plus 153-Sm-EDTMP
were significantly lower compared with the 153-Sm-EDTMP alone
(P < .0001), thus showing Dex-enhanced tumor killing in vivo. Next,
the median survival time of different treatment groups was compared
(Figure 4A). The median survival of mice receiving no therapy was
26.5 days, and treatment with Dex or 153-Sm-EDTMP alone
Figure 2. Dex and radiation induce cell death of myeloma cell lines by apoptotic pathway. (A) JC-1 fluorescence in myeloma and BMSCs
with Dex (5 μM) and/or radiation (6 Gy) treatments at 6 hours after radiation. The data presented are the triplicate averages of the fluores-
cence ratio ± SD and are representative of two independent experiments. For specific cell lines, *P< .01 versus Dex, ζP< .005 versus IR.
ns indicates not significant. (B) Activity of caspase-3 in myeloma (MM.1S, 5TGM1) and BMSCs (HS-5, SR-4987) treated with Dex and/or
radiation. The specificity of caspase-3 activation was confirmedwith the N-Ac-Asp-Glu-Val-Asp-CHO caspase-3 inhibitor. Values presented
are the mean of triplicate values ± SD and are representative of two independent experiments. *P< .001 versus control, ζP< .001 versus
Dex or IR, #P< .05 versus control, £P< .001 versus Dex or IR. ns indicates not significant. (C) Western blot analysis of PARP in myeloma
cells (8226, ANBL-6, MM.1S) after Dex (5 μM) and/or radiation (6 Gy). For each treatment, top panels show full-length and cleaved PARP
fragment (shown by arrows) and bottom panels show tubulin loading control. The blot shown is a representative of three independent
blots. Values of densitometric analysis of cleaved PARP (normalized to tubulin) are shown.
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prolonged median survival to 29 days (P < .05 vs control) and 31 days
(P < .005 vs control), respectively. With a combination of Dex with
153-Sm-EDTMP, the median survival time increased to 44 days
(P = .001 vs control and P < .005 vs 153-Sm-EDTMP or Dex alone;
log rank test). Overall, the BLI and survival studies corroborate our
in vitro results and show that Dex combined with radiotherapy results
in significantly increased killing of BM-resident tumor cells.
To determine whether Dex was affecting 153-Sm-EDTMP–induced
radiotoxicity to hematopoietic system in vivo, we analyzed complete
blood cell counts. When Dex was combined with 153-Sm-EDTMP,
the radiation-induced hematopoietic toxicity to both platelets (Fig-
ure 4B) and granulocytes (Figure 4C ) was significantly less pro-
nounced. For platelets, a nadir value of 190.7 ± 45.1 (×109/L) was seen
on day 18 with 153-Sm-EDTMP alone that was significantly improved
Figure 3. Dex potentiates radiation-mediated killing of myeloma cells cocultured with BMSCs and inhibits IL-6 release from irradiated
BMSCs. (A) 5TGM1-eFP-Luc cells cultured alone or with SR-4987 BMSCs; cocultures were treated with Dex (5 μM) and/or radiation (6 Gy),
and luciferase (Luc) activity was measured at 24 or 48 hours after radiation. Values plotted are mean ± SD of triplicate samples and are
representative of two independent experiments. Results are presented as fold change in Luc activity relative to time 0 (the latter set to 1).
*P< .05 versus control or IR alone, ζP< .005 versus control, Dex alone, or IR alone. (B) Fluorescence images of eFP (5TGM1) and DsRed
(SR-4987) in cocultures at 24 hours after treatment with Dex and/or radiation. Images of untreated control are included. Each photograph is
representative of three wells. Original magnification, ×40. (C) Quantification of IL-6 in culture supernatant by ELISA at 24 hours after 6-Gy
radiation treatment ofmyeloma (5TGM1) or BMSCs (SR-4987), with orwithout Dex (5 μMfor 24 hours) pretreatment. Results are presented
as IL-6 in picograms per milliliter (mean of triplicates ± SD). *P< .05 versus 5TGM1 control, ζP< .005 versus SR-4987 control, #P< .005
versus IR. (D) Proliferation of 5TGM1 myeloma cells with exogenous IL-6 or SR-4987 conditioned medium from nonirradiated (CM) or
irradiated cells (ICCM). MTT activity at 48 hours in untreated controls was set to 1, and results are shown as fold change over this activity.
Results are representative of two independent experiments. *P = .05 versus control, ζP < .005 versus control.
Table 1. BLI-Based Quantitation of Myeloma Burden in Live Mice as Indicative of Responses to
Dex and/or 153-Sm-EDTMP Treatments.
Groups Photons/sec/cm2 (×105)
Day 18 (Mean ± SD) Day 24 (Mean ± SD)
PBS 325.3 ± 22.2 1002.3 ± 134.2
Dex 206.3 ± 55.6 808.7 ± 60.3
153-Sm-EDTMP 203.0 ± 58.2 711.9 ± 109.4
Dex + 153-Sm-EDTMP 178.8 ± 29.1 320.9 ± 52.7
5TGM1-Luc cells were injected intravenously into mice on day 0. Treatment was started on day 12
after tumor inoculation and consisted of Dex and/or 153-Sm-EDTMP treatments as described in
Materials and Methods. BLI signals from the entire abdominal area were calculated using the soft-
ware Living Image (Xenogen). The data represent averaged luminescence intensity from six mice
per group (±SD) and are displayed as photons per second after normalizing for the baseline lumi-
nescence intensity acquired from normal healthy mice.
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by combining Dex with 153-Sm-EDTMP (466.3 ± 42.1 [×109/L],
P = .0001). A similar protection of platelet counts was seen on day 21
with values of 321.1 ± 29.1 and 601.2 ± 28.2 (× 109/L) for 153-Sm-
EDTMP and Dex + 153-Sm-EDTMP, respectively (P < .0001). Dex
was also found to be effective in rescuing peripheral granulocyte counts
from radiotoxicity. In mice treated with 153-Sm-EDTMP alone, a
severe granulocytosis was seen on day 18 that was significantly alle-
viated with Dex plus 153-Sm-EDTMP. Furthermore, on day 21, the
granulocyte counts inmice receiving Dex + 153-Sm-EDTMPwas com-
parable to those in the untreated control group, whereas the counts in
mice receiving 153-Sm-EDTMP alone remained significantly repressed
(P < .005).
From this in vivo study, we conclude that Dex increases 153-Sm-
EDTMP–mediated killing of myeloma cells and ameliorates radiation
toxicity to BM hematopoietic system. On the basis of the observation
that Dex does not radiosensitize BMSCs (Figure 1C ) that are known to
provide a structural scaffold for BM hematopoiesis [48], Dex could
be protecting specialized BM niches thereby restoring hematopoiesis.
Also, combining Dex with radiotherapy may be protecting normal
hematopoietic stem and progenitor cell population from bystander ra-
diation toxicity culminating in less severe myelosuppression.
Combining Dex with 153-Sm-EDTMP Enables
Administration of Two Cycles of 153-Sm-EDTMP with
Further Prolongation of the Survival of 5TGM1 Bearing Mice
We next compared the efficacy of one, versus two-cycle therapy
with Dex and/or 153-Sm-EDTMP (Figure 5). The control animals
Figure 4. In vivo effect ofDex and/or 153-Sm-EDTMPon the survival
and peripheral blood counts in 5TGM1-Lucmodel. (A) Kaplan-Meier
survival curves formice treatedwith one cycle of Dex and/or 153-Sm-
EDTMP relative to survival in the untreated control group. Peripheral
blood cell counts of platelet (B) and granulocyte (C) numbers on
days 12, 18, and 21 after tumor implantation in various groups
shown in panel A. Cell numbers are expressed as the mean ± SD.
*P = .0001 versus 153-Sm-EDTMP, ζP < .0001 versus 153-Sm-
EDTMP on respective days.
Figure 5. Kaplan-Meier survival curves for 5TGM1-Luc mice sub-
jected to either one or two cycles of the Dex and/or 153-Sm-EDTMP
treatments. The first cycle of treatment was initiated on day 12 after
tumor injection. In the two-cycle regimen, the second cycle of treat-
ment was initiated on day 22 where Dex was given on days 22 to 26
and 153-Sm-EDTMPwas given on day 23. Mice were followed until
they reached the humane end point.
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exhibited a median survival of 25 to 26.5 days. One- and two-cycle
regimens with Dex showed a prolongation of the median survival to
28 days (P = .005 vs control) and 32 days (P < .005 vs one-cycle reg-
imen). Treatment with one cycle of 153-Sm-EDTMP resulted in a
modest increase in the median survival time (to 31 days) compared with
that of the control (25 days, P < .005). Two cycles of 153-Sm-EDTMP
did not provide any further increase of the median survival (33.5 days,
P = ns between one- and two-cycle protocols) and mice showed signifi-
cant loss in bodyweight and other signs of radiotoxicity (data not shown).
With Dex and 153-Sm-EDTMP, the median survival of 46 days
was seen with the one-cycle regimen (P = .0001, relative to untreated
controls) that was increased to 64 days with two cycles of Dex plus
153-Sm-EDTMP (P < .01 relative to one cycle of Dex plus 153-Sm-
EDTMP). This in vivo study indicates that Dex may be effectively com-
bined with 153-Sm-EDTMP for repeat dosing of radionuclide to
augment the overall therapeutic efficacy of skeletal targeted radio-
therapy in the treatment of systemic MM.
Dex Induces Myeloma Cell Killing by Increasing
Steady-State Levels Pro-oxidants
Asmyeloma cells may have higher steady-state levels of pro-oxidants
[31], we next analyzed if treatment with Dex and radiotherapy would
result in a further increase in oxidative stress in myeloma cells render-
ing them more susceptible to undergo radiation-induced cell killing.
Clonogenic survival was performed in myeloma cells that were either
treated with Dex or cotreated with NAC (a clinically relevant thiol anti-
oxidant) or the combination of polyethylene glycol (PEG)–conjugated
SOD (scavenges O2
•−) and PEG-catalase (scavenges H2O2) [49]. Treat-
ment with Dex resulted in approximately a 60% and a 50% inhibition
in the clonogenic ability of ANBL-6 and 5TGM1 cells, respectively
(Figure 6A). Both NAC pretreatment and combination of PEG-SOD
and PEG-CAT significantly rescued Dex-mediated clonogenic cell kill-
ing of both cell lines. Overall, Figure 6A demonstrates that induction
of oxidative stress, mediated by ROS, is an important component in
Dex-mediated killing of myeloma cells.
Combination of Dex with Radiation Treatment Results in
Increased Oxidative Stress in Myeloma Cells and Not BMSCs
To determine whether ROS production is involved in Dex-mediated
increased killing of myeloma cells by radiation, DHE oxidation was
measured as a surrogate for O2
•− (Figure 6B). Compared with untreated
cells, the O2
•− production (determined by PEG-SOD inhibitable DHE
oxidation) was significantly elevated in both Dex- or radiation-treated
5TGM1 cells (P < .01). This O2
•− production was significantly increased
with combination treatment of Dex plus radiation (P < .01). In BMSCs,
Dex marginally increased the O2
•− production, yet radiation was found
to increase DHE fluorescence significantly (P < .001). However, com-
bined treatment of Dex and radiation did not further increase the
O2
•− production in BMSCs.
We next assessed the impact of Dex and/or radiation treatment on
the steady-state levels of intracellular pro-oxidants byH2DCF-DA oxi-
dation. PEG-CATwas used to confirm the specificity of the signal for
H2O2 (Figure 6C ). In 5TGM1 cells, relative to the untreated con-
trol, treatment with Dex or radiation resulted in increased PEG-CAT-
inhibitable H2DCF-DA oxidation that was further enhanced in
response to the Dex plus radiation treatment (P < .0001 vs radiation
or Dex), indicating that Dex is augmenting radiation-induced increases
in H2O2 generation in myeloma cells. Furthermore, Dex did not in-
crease radiation-induced H2O2 production in BMSCs (Figure 6C ).
Overall, the results of Figure 6 show that myeloma cells are subject
to increased oxidative stress by Dex treatment that is further increased
with the combined treatment of Dex plus radiation.
Dex Mitigates Radiation-Induced Changes in Pro-oxidant
Levels and Protects the Normal Hematopoietic Stem
and Progenitor Cells from Radiotoxicity
BM harbors the hematopoietic system, and any radiation-based
therapeutic strategy directed toward myeloma cells is expected to cause
acutemyelosuppression by irradiating and depleting the hematopoietic
stem and precursor cell pools [50]. On the basis of Dex-mediated pro-
tection of peripheral blood cell counts (Figure 4, B andC ), we next de-
termined whether Dex could protect the BMhematopoietic system from
radiotoxicity by reducing radiation-induced pro-oxidant production.
Primary HSCs and HPCs were isolated from C57BL/6 mice, and
a representative sorting pattern is shown in Figure 7A. These normal
cells were treated ex vivo with Dex and/or radiation and analyzed for
steady-state levels of pro-oxidants (Figure 7B). Compared with the un-
treated control, treatment with Dex or radiation increased the steady-
state levels of ROS in HSCs that was attenuated by NAC pretreatment.
When HSCs were treated with Dex plus radiation, a decreased steady-
state level of pro-oxidants was noted relative to the level in radiation
alone (P < .05), suggesting that Dex can inhibit the pro-oxidant gen-
eration induced by radiation. Although the combination treatment of
Dex plus radiation did not bring the pro-oxidant levels in HSCs down
to the baseline level, no significant difference was noted when the
oxidation of H2DCF-DA was compared between Dex or Dex plus ra-
diation treatments. Studies were also performed in the primary HPCs
where Dex and radiation alone increased ROS, relative to control. On
combination treatment with Dex plus radiation, the pro-oxidant levels
were significantly lower than those seen with radiation alone (P <
.0005). The results in Figure 7B suggest thatHSCs andHPCs are highly
susceptible to radiation-induced up-regulation of steady-state levels of
pro-oxidants and that Dex can significantly inhibit radiation-induced
oxidative stress in these hematopoietic stem/progenitor cells.
We next determined whether the Dex-mediated inhibition of steady-
state levels of pro-oxidants might lead to a clonogenic survival benefit
after radiation therapy (Figure 7C ). Compared with untreated cells,
radiation inhibited the colony-forming ability of both HSCs and
HPCs (P < .0001 for each cell type). HSCs were found to be relatively
more resistant to radiation toxicity than HPCs presumably because of
the quiescent nature of this cell type. Compared with radiation treat-
ment alone, whenHSCs or HPCs were treated with Dex plus radiation,
the clonogenic survival of both cell types was increased (P < .01). This
result corroborates the findings shown in Figure 7B and suggests that
the proposed combination of Dex plus radiation can inhibit radiation-
induced oxidative stress and improve clonogenic survival of HSCs
and HPCs.
Discussion
Dex is among one of the most clinically effective drugs in myeloma
therapy. In lymphoid malignancies, Dex-induced apoptotic cell death
pathways have been partially deciphered [20,21]. Our results show
that Dex treatment results in the activation of the mitochondrial
apoptotic cascade in myeloma cells (Figure 2), further substantiating
the role of mitochondrial dysfunction in Dex-mediated apoptosis.
Studies have linked Dex-induced apoptosis and oxidative stress using
a thymic lymphoma cell line where clones resistant to H2O2 (by cata-
lase overexpression or selection of H2O2-resistant clones) showed Dex
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cross-resistance [51]. Dex treatment has been shown to upregulate
the messenger RNA expression of glutathione S-transferase and down-
regulate the messenger RNA of thioredoxin, glutathione peroxidase,
catalase, and superoxide dismutase in T lymphocytes [33,34]. How-
ever, in MM, a causal role for oxidative stress in Dex-induced tumor
cell death has not been firmly established. Chauhan et al. [36] showed
that Dex-induced apoptosis of myeloma cells is independent of O2
•−
production. However, it was recently shown that newly diagnosed
myeloma patients treated with Dex exhibit gene expression changes
indicative of oxidative stress [37]. In the current report, we show for
the first time that besides various other known myeloma cell death
mechanism(s), Dex increases oxidative stress–induced clonogenic cell
killing in myeloma cells (Figure 6A).
Newly diagnosed MM patients have higher circulating levels of
malondialdehyde indicative of lipid peroxidation and lower levels of
antioxidant enzymes (superoxide dismutases, glutathione peroxidases,
and catalase) in erythrocytes [30–32]. Because myeloma patients may
be under systemic oxidative stress at diagnosis, treatment with agents
that selectively induce oxidative stress (chemotherapy and radiotherapy)
in tumor cells may significantly enhance their oxidative cytolysis. In sup-
port of this hypothesis, our in vitro studies with combined exposure to
Dex and radiation clearly show an increase in Dex-induced oxidative
stress (Figure 6,B andC ) that seems to be causally related to a significant
decrease in clonogenic survival of myeloma cells (Figure 1C ). Further-
more, Dex-induced increases in oxidative stress and cell killing were
not noted in BMSCs, thus not worsening hematopoietic recovery after
radiotherapy as also seen by peripheral blood cell counts (Figure 4,B and
C ). This leads to the speculation that the combination of Dex with
radiation may increase the therapeutic index of skeletal targeted radio-
therapy in MM by selectively inducing oxidative stress in cancer cells.
Our studies show that in contrast to myeloma cells, Dex inhibited
radiation-induced oxidative stress in normal hematopoietic stem and
Figure 6. Dex induces ROS-mediated clonogenic cell death of myeloma cells and potentiates radiation-induced ROS levels in myeloma
cells but not in BMSCs. (A) Clonogenic survival of myeloma (ANBL-6 or 5TGM1) after Dex (5 μM for 24 hours) combined with or without
NAC or PEG-SOD and PEG-CAT. Results are expressed as the NSF of triplicate cloning wells and are representative of two independent
experiments. *P < .001 versus Dex, ζP < .001 versus NAC, #P < .01 versus Dex. Effect of Dex (5 μM) and/or 6-Gy radiation in myeloma
(5TGM1) and BMSCs (SR-4987) on the steady-state levels of (B) O2
•− in the presence of PEG-SOD (*P < .01 vs control, ζP< .01 vs Dex or
radiation) or (C) H2O2 in the presence of PEG-CAT (*P < .005 vs control,
ζP < .0001 vs Dex or radiation). For panels B and C, values are
averages of triplicate ± SD and calculated by subtracting the fluorescence value measured in the presence and absence of PEG-SOD or
PEG-CAT, respectively. ns indicates not significant.
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progenitor cells (Figure 7B). We hypothesize that Dex attenuates
radiation-induced cytotoxicity to HSCs and HPCs by decreasing
steady-state levels of pro-oxidants to a threshold level that may be
aiding in improved hematopoietic reconstitution. Our in vivo studies
show that Dex cotreatment results in less severe and faster peripheral
blood reconstitution of blood cell types (granulocytes and platelets)
compared with radiotherapy alone (Figure 4, B and C ). In erythroid
cells, a hematoprotective role of Dex with chemotherapeutic drugs
has been shown where it stimulates a sustained proliferation of im-
mature cells and delays their differentiation [52]. Recently, ROS has
been shown to act as a positive regulator of hematopoietic reconstitu-
tion by upregulating vascular cell adhesion molecule 1 expression on
endothelial cells [53]. To assess whether Dex was protecting hemato-
poietic stem/progenitor cells from radiation-induced damage, clono-
genic survival of HSC/HPC was performed where the progenitor
number of different lineages (myeloid and lymphoid lineages, com-
mon myeloid progenitor, and common lymphoid progenitor subsets)
was collectively analyzed. Compared with radiation alone, Dex co-
treatment showed higher clonogenic survival of both HSCs and HPCs
(Figure 7C ), suggesting that the improved in vivo restoration of normal
hematopoiesis after combination treatment with Dex plus 153-Sm-
EDTMP could be partially rendered by Dex-mediated radioprotection
of HSCs and HPCs.
In the present study, we have focused on the myeloma cell propro-
liferative cytokine IL-6 [54] that is released by irradiated BMSCs (Fig-
ure 3C ). It is well established that radiation treatment upregulates
redox-sensitive transcriptional factors (i.e., NF-κB and AP-1) [55] that
have been shown to increase IL-6 production in MM cells [27]. Dex
has also been shown to inhibit radiation-induced IL-6 up-regulation
in fibroblasts [56]. Mechanistically, Dex can inhibit constitutive and
radiation-induced IL-6 production by binding and inhibiting NF-κB
[57] or upregulating the transcription of IκB [58] or glucocorticoid-
induced leucine zipper that can inhibit NF-κB and AP-1 [59–61].
Using myeloma-BMSCs coculture studies, we show that IL-6 as well
as other radiation-induced pro-inflammatory cytokines may be stim-
ulating myeloma growth and proliferation, and this paracrine cytokine
stimulation can be effectively inhibited by Dex (Figure 3C ) with selec-
tive radiosensitization of myeloma cells.
To evaluate the efficacy of the proposed combination therapy for
Dex plus radiation, studies were extended in an animal model (Fig-
ures 4 and 5). We have previously shown that the in vitro cell killing of
a chemoradiotherapy regimen with γ-radiation can be effectively re-
produced in vivo with 153-Sm-EDTMP [42]. Cotreatment of Dex
with 153-Sm-EDTMP resulted in inhibition of myeloma disease pro-
gression and improved survival (Figure 4). With 153-Sm-EDTMP,
87.5% of the radiation dose would be delivered to the BM in three
half-lives (>6 days). We therefore tested a two-cycle protocol where
153-Sm-EDTMP was administered 10 days apart that also gave time
for Dex-mediated recovery of the peripheral blood counts. A two-cycle
protocol of Dex plus 153-Sm-EDTMP prolonged the survival over
one-cycle protocol (Figure 5), indicating that cotreatment with Dex
may be used for designing a repeat dosing regimen of bone-seeking
radionuclide and/or for escalation of radiation dose to improve the
therapeutic outcome of MM.
Dex is among one of the most clinically effective drugs in myeloma
therapy [62] that is used in chemotherapy protocols with novel molec-
ularly targeted agents such as bortezomib and thalidomide [63]. When
combined with radiation treatment, an increased myeloma cell killing
of thalidomide [13] and bortezomib [14,15] has been noted. In our
previous study, the combination of bortezomib with 153-Sm-EDTMP
resulted in the prolongation of survival without increasing the myelo-
suppressive effects of 153-Sm-EDTMP [42]. The current report shows
that the combination of 153-Sm-EDTMP with Dex selectively radio-
sensitizes myeloma cells in vivo and partially alleviates radiotoxicity
Figure 7. Dex inhibits radiation-inducedoxidative stress and alleviates
radiation toxicity in HSCs and HPCs. (A) Representative flow cyto-
metry profile of isolation of HPCs and HSCs used in panels B and C.
(B) Intracellular levels of pro-oxidants in HSCs or HPCs treated with
Dex and/or radiation with or without NAC asmeasured by H2DCF-DA
oxidation. The values are normalized to those for untreated controls
and are representative of two independent experiments. *P < .001
versus control, ζP< .05 versus radiation, τP< .0005 versus radiation.
(C) Clonogenic survival of HSCs and HPCs treated with Dex and/or
radiation normalized to the survival of untreated control cell popula-
tions. Three cloning replicates were counted for each treatment and
results are representative of two independent experiments. *P <
.0001 versus control, ζP < .01 versus radiation.
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toward the BM hematopoietic system. Mechanistically, we show that
the combination of radiotherapy and Dex selectively enhances killing
of myeloma cells while protecting normal BM hematopoiesis through
a mechanism that involves selective increases in oxidative stress in
myeloma cells. The results of this study can be extended for myeloma
therapy in combination with bortezomib, thalidomide, or other novel
biologic agents that may enhance the potency of Dex and/or radiation
in killing myeloma cells. To our knowledge, this is the first report
showing that Dex significantly and specifically enhances radiation-
induced oxidative stress and killing of myeloma cells in monocultures,
direct cocultures, and in vivo in a myeloma model. Our findings in
normal tissues suggest that Dex decreases hematotoxicity and increases
the overall therapeutic index of radiotherapy in MM. This study pro-
vides a potential new avenue for therapeutic use of Dex in designing
protocols for myeloma therapy. Furthermore, the proposed combina-
tion of Dex and radiation can be tested in other malignancies because
both these treatment modalities are widely used in various cancers.
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